Market Report

Market Report by Email

If you would like to receive the daily Market Report by email please fill out your name and email address in the sign-up form below and you will be added to our mailing list.

* indicates required

Please select all the ways you would like to hear from Ramsey Crookall:

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our email marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing.

Learn more about Mailchimp's privacy practices here.

Tuesday,12 November 2024 at 08:16

UK & European markets opened lower, as investors assess what U.S. President-elect Donald Trump’s return to the White House could mean for the region’s economy amid worries about possible tariffs.

Asia-Pacific markets fell after China’s latest stimulus measures underwhelmed and its October inflation numbers came in lower than expected, prompting concerns over the recovery in the world’s second-largest economy.

Gold fell to its lowest in nearly two months, weighed down by a stronger dollar, while investors awaited a set of key U.S. economic data and comments from Federal Reserve officials for further clarity on the interest rate trajectory.

Oil prices eased as investor disappointment over China's latest stimulus plan and oversupply concerns weighed on the market, along with a stronger dollar.

In corporate news, AstraZeneca reported a strong financial performance for the first nine months of the year, with a 19% increase in revenue driven by solid growth in oncology, CVRM, respiratory, and rare diseases, leading to upgraded full-year guidance.

The FTSE 100 pharma giant said it had also submitted a new biologics licence application for datopotamab deruxtecan in EGFR-mutated non-small cell lung cancer, informed by phase two and three trial data, while withdrawing a prior BLA for a broader indication.

Additionally, AstraZeneca announced positive phase three trial results for Koselugo in adults with neurofibromatosis type 1, as well as a $3.5bn investment to expand its research and development and manufacturing footprint in the United States. 

Markets
08:15
FTSE 100 8,080 (-0.55%)
FTSE 250 20,579 (-0.70%)
DAX 19,265 (-0.94%)
the close
Dow Jones 44,293 +0.69%
S&P 500 6,001 +0.10%
NASDAQ 19,298 +0.06%
Fixed Income
UK 10-YR YIELD 4.455
Exchange Rates
GBP/USD 1.280
GBP/EUR 1.204
Commodities
Gold $2,603 (-0.59%)
Brent $71.89 +0.20%
Important - No news or research item should be construed as a recommendation to trade. The inclusion of securities within this report does not necessarily imply their suitability for individual portfolios or situations in respect of which further advice should be sought. Information contained in this report has been compiled from sources believed to be reliable but is not warranted to be accurate or complete.

We use cookies to improve your experience on our website.
By continuing to browse, you agree to our use of cookies. Cookie Policy

Accept
Members of the London Stock Exchange and PIMFA | Licensed by the Isle of Man Financial Services Authority (IoMFSA) Registered Office: Ramsey Crookall and Co. Ltd., 38/42 Athol Street, Douglas, Isle of Man, IM1 1QH
Copyright © 2023 - Ramsey Crookall & Co. Ltd
Building Personal Finance Futures London Stock Exchange